Stock CTNM CONTINEUM THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Contineum Therapeutics, Inc.

Equities

CTNM

US21217B1008

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 07/06/2024 BST 		5-day change 1st Jan Change
16.31 USD +1.18% Intraday chart for Contineum Therapeutics, Inc. +6.46% 0.00%
06-03 Contineum Therapeutics, Inc. Appoints John Healy as General Counsel & Corporate Secretary CI
05-20 Contineum Therapeutics, Inc. Appoints Troy Ignelzi as Independent Member of Its Board of Directors and as Chair of the Audit Committee CI

Valuation

Fiscal Period: December 2024 2025 2026
Capitalization 1 419.5 - -
Enterprise Value (EV) 1 215.8 359.8 350
P/E ratio - - -
Yield - - -
Capitalization / Revenue - 28 x -
EV / Revenue - 24 x -
EV / EBITDA -4.98 x -7.72 x -4.88 x
EV / FCF -5.83 x -8.57 x -5.15 x
FCF Yield -17.1% -11.7% -19.4%
Price to Book - -8.86 x 7.06 x
Nbr of stocks (in thousands) 25,723 - -
Reference price 2 16.31 16.31 16.31
Announcement Date - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2023 2024 2025 2026
Net sales 1 - - 15 -
EBITDA 1 - -43.33 -46.6 -71.78
EBIT 1 - -45.95 -40.9 -80.07
Operating Margin - - -272.64% -
Earnings before Tax (EBT) 23.17 - - -
Net income 22.72 - - -
Net margin - - - -
EPS - - - -
Free Cash Flow 1 - -37 -42 -68
FCF margin - - -280% -
FCF Conversion (EBITDA) - - - -
FCF Conversion (Net income) - - - -
Dividend per Share - - - -
Announcement Date 15/02/24 - - -
1USD in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - - - -
EBITDA - - - -
EBIT 1 -9.93 -9.5 -12.6 -15.7
Operating Margin - - - -
Earnings before Tax (EBT) - - - -
Net income - - - -
Net margin - - - -
EPS - - - -
Dividend per Share - - - -
Announcement Date 16/05/24 - - -
1USD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2023 2024 2025 2026
Net Debt 1 - - - -
Net Cash position 1 - 204 59.7 69.5
Leverage (Debt/EBITDA) - - - -
Free Cash Flow 1 - -37 -42 -68
ROE (net income / shareholders' equity) - - - -663%
ROA (Net income/ Total Assets) - - - -
Assets - - - -
Book Value Per Share 2 - - -1.840 2.310
Cash Flow per Share - - - -
Capex 1 - 0.43 0.35 0.55
Capex / Sales - - 2.34% -
Announcement Date 15/02/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
16.31 USD
Average target price
28 USD
Spread / Average Target
+71.67%
Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
CONTINEUM THERAPEUTICS, INC. Stock Contineum Therapeutics, Inc.
0.00% 420M
MODERNA, INC. Stock Moderna, Inc.
+51.85% 57.87B
LONZA GROUP AG Stock Lonza Group AG
+41.42% 40.25B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.25% 39.94B
CELLTRION, INC. Stock Celltrion, Inc.
-5.16% 28.54B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+12.79% 26.4B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.18% 19.33B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.88% 12.4B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.61% 12.23B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.06% 12.2B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. CTNM Stock
  4. Financials Contineum Therapeutics, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW